Clinical study with Gedea Biotech’s antibiotics-free vaginal infections treatment published in European Journal of Obstetrics & Gynecology and Reproductive Biology
Gedea Biotech today announced the publication of a new peer-reviewed scientific manuscript in the European Journal of Obstetrics & Gynecology and Reproductive Biology, presenting clinical data on the effects of the company's treatment for vaginal infections, pHyph®, on bacterial vaginosis (BV)…
Gedea Biotech’s pHyph recognised in updated Swedish clinical guideline for bacterial vaginosis
Gedea Biotech today announced that its first-in-class vaginal tablet, pHyph®, is now mentioned and described in a major Swedish national clinical guideline for the treatment of bacterial vaginosis (BV), marking an important step in becoming a clinically recognised treatment option. The updated…
Gedea Biotech completes VVC-2025 study and advances product expansion to treat vaginal fungal infections
Gedea Biotech today announced continued progress in its strategy to expand the CE-marked indications for pHyph to include the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal fungal infection. The company has completed the clinical study, VVC-2025 and continues to advance the…
Gedea Biotech successfully completes clinical study BV2025 for pHyph
Lund, Sweden – 22 July 2026 Gedea Biotech today announced the successful completion of the BV2025 post market clinical study. The study with the vaginal tablet pHyph met its primary endpoint confirming the favourable safety and tolerability in women with bacterial vaginosis (BV). Clinical cure…
Gedea Biotech announces the start of the clinical study VVC2025—first patients enrolled
PRESS RELEASE Gedea Biotech today announced the start of the clinical study VVC2025, following approval from the Swedish Medical Products Agency (Läkemedelsverket). The randomized and controlled study evaluates Gedea’s product pHyph for the relief of signs and symptoms of vulvovaginal candidiasis…
Gedea Biotech strengthens IP portfolio with new European patent for treating infections with GDL
PRESS RELEASE Gedea Biotech today announced that European patent no. 3 691 625 has entered into force, further strengthening Gedea’s intellectual property protection for pHyph in Europe, until 2038. The patent covers the use of glucono delta-lactone (GDL) for the treatment of bacterial vaginosis…
Gedea Biotech strengthens IP portfolio with new US patent for vaginal formulation
PRESS RELEASE Gedea Biotech today announced that the company has been granted a US patent for its vaginal formulation (patent no. 12,496,288). The patent marks an important step for Gedea Biotech in protecting the product on the US market and is expected to be of high strategic value for future…
Gedea Biotech appoints Julie Waras Brogren as new CEO to lead the company into its commercialization phase
Gedea Biotech today announces a planned CEO transition. After close to ten years as CEO, Annette Säfholm has decided to step down from her role. The Board of Directors has appointed Julie Waras Brogren as the new Chief Executive Officer. Julie has more than 20 years of experience from the…
Gedea Biotech announce start of the clinical study BV2025 following CE marking of pHyph —first patients enrolled
PRESS RELEASE Lund, Sweden, January 22, 2026 Gedea Biotech today announced that the clinical trial BV2025 has started, following approval from the Swedish Medical Products Agency (Läkemedelsverket) for the treatment of bacterial vaginosis. In addition to fulfilling post-approval requirements, the…
Gedea Biotech strengthens its Board with extensive commercial expertise to support next phase
PRESS RELEASE Lund, Sweden – November 18, 2025 Gedea Biotech, an innovative Swedish life science company in women’s health, today announced the appointment of three new members to its Board of Directors: Paan Hermansson, Berit Lindholm, and Caroline Mofors. “- We are very fortunate to bring strong…